Juno Therapeutics' (JUNO) Treatment of Chronic Lymphocytic Leukemia Granted FDA Orphan Drug Status

October 6, 2016 9:14 AM EDT

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Juno Therapeutics' (NASDAQ: JUNO) treatment chronic lymphocytic leukemia was granted FDA orphan drug status.

Generic Name:autologous CD4+/CD8+ T cells expressing a CD19 chimeric antigen receptor (CAR) and a truncated epidermal growth factor receptor.
Trade Name:N/A
Date Designated:10/04/2016
Orphan Designation:Treatment of chronic lymphocytic leukemia
Orphan Designation Status:Designated
FDA Orphan Approval Status:Not FDA Approved for Orphan Indication
Marketing Approval Date:N/A
Approved Labeled Indication:
Exclusivity End Date:N/A
Juno Therapeutics, Inc.
307 Westlake Avenue
Suite 300
Seattle, Washington 98109

The sponsor address listed is the last reported by the sponsor to OOPD.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA, Trader Talk

Add Your Comment